Eric Bhatt

Eric Bhatt is a leading investigator in personalized neoantigen-specific TCR therapy at the National Cancer Institute. His research has established methods for rapidly identifying patient-specific neoantigens and engineering T cells with matching TCRs. He has demonstrated clinical proof-of-concept for neoantigen TCR therapy in gastrointestinal cancers and other solid tumors. His work has helped transform neoantigen targeting from a research concept into a viable therapeutic modality.